Animal Healthcare Market Analysis | Coherent Market Insights

1. Coherent Market InsightS Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. Regenerative Therapies Market Analysis (2020-2027) • Regenerative therapies deliver specific types of cells or cell products to diseased tissues or organs to restore tissue and organ function. Materials used in regenerative therapies release growth factors and cytokines back into the damaged tissue to aid the healing process. • The global regenerative therapies market is estimated to account for US$ 10,421.5 Mn in terms of value in 2019 and is expected to reach US$ 45,940.7 Mn by the end of 2027

3. Global Regenerative Therapies Market: Drivers • Increasing prevalence of cardiovascular diseases (CVDs) is expected to propel growth of the global regenerative therapies market over the forecast period. For instance, according to the American Heart Association's Heart and Stroke Statistics 2019 Update, around 48% of all adults in the U.S. suffered from some type of CVD in 2016. • Moreover, increasing focus on tissue-cell and stem cell research is also expected to aid in growth of the market. For instance, in March 2020, researchers from Dankook University and Catholic University, South Korea, reported investigation of the types and degrees of physical and psychological discomfort experienced by hematopoietic stem cell donors before, during, and after the donation process.

4. s • Allograft held dominant position in the global regenerative therapies market in 2019, accounting for 57.7% share in terms of value, followed by xenograft and alloplast, respectively.

5. Global Regenerative Therapies Market: Restraints • Lack of standardized guidelines on tissue and bio-medical engineering is expected to hinder growth of the global regenerative therapies market. Lack of standardized guidelines on biomedical and tissue engineering and stem-cell research across regions is hampering production and approval of regenerative therapies. This in turn increases cost burden of regulatory approval for product makers. • Moreover, high gestation period and time-to-market due to lengthy clinical trials is also expected to limit growth of the market. A prime pitfall in development of new innovative regenerative therapies is lengthy clinical trial process. The process becomes lengthy due to acute dearth in availability of clinical trial subjects, who usually do not want to participate in such trials. Long gestation period often leads to abandonment of clinical trials midway, creating both financial as well as loss of ideas.

6. Global Animal Healthcare Market: Restraints • A lack of surveillance and diagnostics for zoonotic diseases in developing economies is expected to hinder growth of the global animal healthcare market.  • Moreover, stringent regulations over use of antibiotics in animal feed is also expected to limit growth of the market. For instance, in the U.S. state of California Senate Bill 27—known as SB 27—aims to minimize the feeding of antibiotics to animals and it prohibits the use of antibiotics “solely for purposes of promoting weight gain or improving feed efficiency.”

7. s • Statistics: • The Production Animal segment was valued at US$ 26,374.5 Mn in 2019 and is forecast to reach a value of US$ 39,159.8 Mn by 2027 at a CAGR of 5.1% between 2019 and 2027

8. Market Trends/Key Takeaways • In the U.S., beef export has declined, which is expected to hinder growth of the market. For instance, according to the USDA National Agricultural Statistics Service (NASS), in November 2019, beef exports from the U.S. totaled 245 million pounds, 21 million pounds below the November 2018 total. • Asia Pacific is expected to witness significant growth in the market, owing to increasing production of milk. For instance, according to the UN's Food and Agriculture Organization (FAO), in 2018, India produced 186 million tons of milk, which was 22% of that year's global total milk production of 843 million tons.

9. Regulations • North America • In order to reduce the use of antibiotics as growth promoters in animals, the Danish Veterinary and Food Administration (DVFA) restricted the use of fluoroquinolones(banned) and cephalosporinsin 2002. In 2010, an industrial voluntary ban (Sweden, France and Denmark) on the use of cephalosporins was implemented for a 2-year period, and a Yellow Card initiative was implemented in Denmark, targeting the largest consumers of antibiotics in the swine production industry. As a result, the consumption of antibiotics from January 2011 to June 2011 was 25 % lower compared to the same period the previous year.

10. 2005: FDA banned the use of Baytril – a fluoroquinoloneantibiotic – also known as enrofloxacin – in chicken and turkey. The antibiotic leads to the emergence of antibiotic resistant bacteria such as Campylobacter in humans, as its chemical composition is similar to that of Cipro – a human antibiotic – which is a common prescription drug to treat foodborne illnesses in humans. 2012: Maryland banned the usage of arsenic-based drugs in chicken feed. However, it is used across other states in the U.S. The drug received FDA approval as its arsenic content is within safe limits for human consumption. 2014: The FDA directed 26 major pharmaceutical companies in the U.S. to cease production of weight-gain drugs for animals by December 2016. It further directed the companies to stop OTC sales of antimicrobials such as Roxarsone (sold under the brand 3-Nitro) administered to livestock through feed and water, which are also used in human medicine. The objective of this move is to reduce health risks associated with the consumption of antimicrobial treated meat products. Ractopamine hydrochloride – a growth promoter drug – is banned in Europe and 160 other countries such as China, Taiwan, Russia, India, Turkey, Iran, Egypt, Kenya and Zimbabwe. However, its use is permitted in the U.S., Brazil and Canada to increase muscle production in swine, turkey and cattle. Since December 2012, meat imports in Russia from countries such as the U.S. is subject to ractopamine-free certification.

11. GROUP I. Drugs with No Allowable Extra-label Uses in Any Food-producing Animal Species • CHLORAMPHENICOL • CLENBUTEROL • DIETHYLSTILBESTEROL (DES) • FLUOROQUINOLONE–CLASS ANTIBIOTICS • GLYCOPEPTIDES — all agents, including VANCOMYCIN • MEDICATED FEEDS • NITROIMIDAZOLES-all agents, including DIMETRIDAZOLE, IPRONIDAZOLE, METRONIDAZOLE and others • NITROFURANS — all agents, including FURAZOLIDINE, NITROFURAZONE and others

12. GROUP III. Drugs with Special Restrictions for Grade "A" Dairy Operations • Grade A Pasteurized Milk Ordinance • NON-MEDICAL GRADE DIMETHYLSULFOXIDE (DMSO) — no use or storage allowable • DIPYRONE — no use allowable • COLLOIDAL SILVER — no use or storage allowable • SYSTEMICALLY–ACTING DRUGS THAT ARE APPLIED TOPICALLY (including Fenthion, Famphur and Xylene, Phosmet, Levamisole and all ivermectins and avermectins — no use allowable

13. GROUP II. Drugs with Restricted Extra-Label Uses in Food-Producing Animal Species • ADAMANTANE & NEURAMINIDASE INHIBITORS in all poultry, including ducks– these agents are approved for treatment or prevention of influenza A • CEPHALOSPORIN–CLASS ANTIBIOTICS except CEPHAPIRIN in all classes of cattle, chickens, pigs and turkeys– ELDU restrictions apply to ALL PRODUCTION CLASSES OF MAJOR FOOD-ANIMAL SPECIES. • 1) No ELDU for purpose of disease prevention • 2) No ELDU that involves unapproved dose, treatment duration, frequency or administration route • 3) Agent must be approved for that species and production class

14. S • – ELDU restrictions DO NOT APPLY to minor–use food animal species. • GENTIAN VIOLET — prohibited for use in food or feed of food-producing animal species • INDEXED DRUGS — some exceptions for minor-use species • PHENYLBUTAZONE — in female dairy cattle (20 months of age or older) • SULFONAMIDE–CLASS ANTIBIOTICS — in lactating dairy cattle– approved uses are allowed for Sulfadimethoxine, Sulfabromomethaz

15. Segmentation:

16. Global Animal Healthcare Market: Competitive Landscape • Major players operating in the global animal healthcare market include, Bayer AG, BoehringerIngelheim GmbH, Cargill, Inc., Ceva Santé Animale, Eli Lilly and Company, Koninklijke DSM N.V., Merck & Co., Inc., Novartis AG, Nutreco N.V., Sanofi S.A., SeQuent Scientific Ltd., Virbac S.A., Vétoquinol S.A., and Zoetis Inc.

17. Global Animal Healthcare Market: Key Developments  • Major players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in 2018, BoehringerIngelheim Animal Health collaborated with Kamraan Veterinary Medicine Co. Group, a veterinary medicine wholesaler and retailer in U.A.E, for marketing veterinary medicines. • Major players in the market are also focused on launching new products to expand their product portfolio. For instance, in March 2020, Kinetic Vet, an animal health company, launched ArmourGuard RTU, an EPA-approved spray-on antimicrobial biosecurity solution that provides continual antimicrobial activity against microorganisms for up to 90 days.

18. Request sample copy here • Request PDF brochure here • Request Customization here • Talk to Analyst • Buy Now • Reference: • https://www.coherentmarketinsights.com/market-insight/animal-healthcare-market-3708

19. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. • What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

20. Contact Us: • Mr. Shah • Coherent Market Insights Pvt. Ltd. • Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S. • Phone: +1-206-701-6702 • Email :sales@coherentmarketinsights.com

21. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/